Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896718 | 0.90 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9895936 | 0.86 | CNR2 (0.83) | CNR2CNR1 | |
| SCHEMBL3406899 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9895909 | 0.80 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9894674 | 0.78 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9897076 | 0.78 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9895701 | 0.78 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL3408597 | 0.76 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL843482 | 0.75 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL9895235 | 0.72 | CNR2 (0.68) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2012-06-14 | — | — | US | claimed |
| EP-2432763-A1 | 1,4 DIHYDROPYRIDINE DERIVATIVES AND THEIR USES | Université de Lille 2 Droit et Santé (FR) | 2012-03-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.